Column
- HOME
- Column
You can view the research column published every month by SMC Laboratories.
2025.02.02
Pre-clinical studies for Liver Cancer: STAM model
For Today’s topic, I would like to focus on Hepatocellular Carcinoma (HCC). We have summarized the characteristics of the various liver cancer models, and you can learn more about them by clicking on the link below. If you are interested in learning about how to prevent and treat liver cancer, please read on. …
2025.02.02
Characterization of a lung fibrosis model and its usefulness
We offer the Idiopathic Pulmonary Fibrosis (IPF) model as a potential model for the development of therapeutics for lung fibrosis, and many of our customers have used this model through our introduction of its usefulness. What is Bleomycin-Induced model for Idiopathic Pulmonary Fibrosis? Bleomycin is a chemotherapeutic agent used to treat cancer, but…
2025.02.02
Interesting relevance between liver cancer patients and our cancer mouse model
Do you have any interest in liver cancer, hepatocellular carcinoma (HCC), or doing research about HCC? We hope the relevant information between HCC and the STAMTM model will be useful to you. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, the fifth most frequent form of cancer, and the third…
2025.02.02
STAM mice develop NASH-derived hepatocarcinoma
Last year, the following article was even published in Nature Reviews Gastroenterology & Hepatology. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention –What is liver cancer? Liver cancer is the sixth most common cancer in the world and the third most common cause of cancer-related death in 2020. Among them, hepatocellular carcinoma…
2025.02.02
Combination Therapies for NASH
It is now accepted that many factors are involved in exacerbating the NASH pathophysiology such as lipotoxicity, oxidative stress, microbiome and immune cell mechanisms. To date, numerous molecules with different mechanisms of action have been developed to treat NASH, although reported efficacy to date has been limited. Considering the complexity of the pathophysiology, many companies…
2025.02.02
Pre-clinical studies for NASH: CDAHFD mice model
Today, we would like to give you a brief introduction to the choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD)-induced NASH model. The CDAHFD model is a non-obese NASH model that is induced by feeding the test animals a choline-deficient, L-amino acid-defined, high-fat diet. The model reproduces NASH phenotypes such as marked steatosis, immune cell infiltration and…
2025.02.02
Case study of preclinical studies for NASH
Among our lineup is the STAM™ model, which is our proprietary model that shows a 100% progression rate from NASH-HCC. This model also boasts a high clinical correlation and has been featured in over 70 papers and more than 80 presentation. What is more, over 10 of our clients that have used this model have…
2025.02.02
Drug Efficacy Studies in Custom Model_ Muscular Dystrophy Mouse Model
In order to meet the diversifying needs of our clients, we often use our years of expertise conducting preclinical animal models to help our clients establish custom models that are not currently on our lineup. This process involves evaluating the potential efficacy of a model based on the available literature and then running the model…
2025.02.02
Preclinical studies for COPD research: PPE model
We would like to share with you about our Porcine pancreatic elastase (PPE)-induced pulmonary emphysema model, known as a disease model for chronic obstructive pulmonary disease (COPD). This model develops pulmonary emphysema due to elastin degradation in the lung tissue and consequent immune cell infiltration caused by elastin fragments. Here at SMC, we use a Microsprayer…
2025.02.02
Change in concept from non-alcoholic fatty liver disease to metabolic disorder related fatty liver disease
You may be aware of NAFLD (non-alcoholic fatty liver disease), but have you heard of MAFLD? Metabolic dysfunction-associated fatty liver disease is a new concept in the understanding of fatty liver disease and it’s pathogenesis. A consensus statement on this disease concept was published in the Journal of Hepatology in 2020. Nonalcoholic fatty liver…
We can help you advance your research.